CelLBxHealth (FRA:DWV) EPS without NRI: €-0.04 (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CelLBxHealth EPS without NRI?

CelLBxHealth FRA:DWV +3.23% EPS without NRI is €-0.04 as of Jun. 2026. The stock has 6 warning signs investors should review. Among 159 Medical Diagnostics & Research companies, CelLBxHealth ranks better than 54.09% on this metric.

CelLBxHealth's earnings per share without non-recurring items for the six months ended in Jun. 2026 was €-0.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.04.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 13.10% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for CelLBxHealth's EPS without NRI or its related term are showing as below:

FRA:DWV' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -75.9   Med: 0   Max: 16.1
Current: 13.1

During the past 13 years, CelLBxHealth's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 16.10% per year. The lowest was -75.90% per year. And the median was 0.00% per year.

FRA:DWV's 3-Year EPS without NRI Growth Rate is ranked better than
54.09% of 159 companies
in the Medical Diagnostics & Research industry
Industry Median: 10.8 vs FRA:DWV: 13.10

CelLBxHealth's EPS (Diluted) for the six months ended in Jun. 2026 was €-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.04.

CelLBxHealth's EPS (Basic) for the six months ended in Jun. 2026 was €-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.04.


CelLBxHealth  (FRA:DWV) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


CelLBxHealth EPS without NRI Related Terms


CelLBxHealth EPS without NRI Historical Data

* Premium members only.

The historical data trend for CelLBxHealth's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CelLBxHealth EPS without NRI Chart

CelLBxHealth Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.08 -0.10 -0.09 -0.06 -0.07

CelLBxHealth Semi-Annual Data
Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.02 -0.03 -0.03 -0.01

FRA:DWV vs TMO, DHR, IDXX: EPS without NRI Comparison

For the Diagnostics & Research subindustry, CelLBxHealth's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CelLBxHealth PE Ratio without NRI vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CelLBxHealth's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where CelLBxHealth's PE Ratio without NRI falls into.



CelLBxHealth EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-0.04 mean?
CelLBxHealth (FRA:DWV) has a EPS without NRI of €-0.04 as of Jun. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on CelLBxHealth and its competitors. According to the industry distribution chart, CelLBxHealth ranks #73 out of 159 companies in the Medical Diagnostics & Research industry, placing it in the top 45.9%.
Is CelLBxHealth's EPS without NRI too high?
CelLBxHealth's current EPS without NRI is €-0.04. Based on the distribution chart, CelLBxHealth ranks #73 out of 159 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does CelLBxHealth's EPS without NRI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, CelLBxHealth ranks #73 out of 159 companies for EPS without NRI. This puts CelLBxHealth in the upper half of its industry. The industry median EPS without NRI is 10.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.80, based on 159 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on CelLBxHealth and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CelLBxHealth's current EPS without NRI is €-0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
Based on GuruFocus' analysis, CelLBxHealth (FRA:DWV) is currently considered Possible Value Trap. The stock's GF Value™ is €0.04, compared to a current price of €0.02 — trading 60% below its estimated fair value. The current EPS without NRI is €-0.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For CelLBxHealth (FRA:DWV), the current EPS without NRI is €-0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CelLBxHealth Business Description

Other Exchanges ANPCF:USACLBX:UK
Address 10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.